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Nandrolone (19-nortestosterone) is an anabolic androgenic steroid commonly abused for
doping purposes. Nandrolone is mainly metabolized in the liver into 19-norandrosterone
prior to glucuronidation and excretion through urine over an extended period of time. Sev-
eral UGTs (i.e., UGT2B7, UGT2B15, and UGT2B17) are thought to be the major enzymes
responsible for conjugation of androgens in human. An in vitro study using recombinant
enzymes expressed in insect cells showed that UGT1A4 and UGT2B7 are the two main
enzymes responsible of 19-norandrosterone glucuronidation. However, the identity of the
enzyme involved in nandrolone metabolism in vivo together with their relative contribu-
tion and regulation remain unknown. Inhibition assays using human liver microsomes
(HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7
and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of
the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the
19-norandrosterone glucuronidation by 35 and 45%, respectively. HLM were genotyped
for UGT2B15 D85Y, UGT2B7 H268Y, and the UGT2B17 deletion polymorphism. The glu-
curonidation activity on 19-norandrosterone was significantly higher in UGT2B15 DD than in
the other UGT2B15 genotypes (p<0.05). Moreover, human liver cancer HepG2 cells were
exposed to androgens to determine if the transcriptional activity of the genes of interest
was affected. Only UGT2B7 mRNA expression was significantly increased (1.8-folds) after
incubation with nandrolone decanoate.These results show that the UGT2B7 and UGT2B15
are involved in 19-norandrosterone glucuronidation and that the UGT2B15 polymorphism
(D85Y) is the only UGT genetic variation that influences the glucuronidation activity. This
could partly explain the inter-individual variation in 19-norandrosterone excretion.
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INTRODUCTION
Nandrolone or 19-nortestosterone (19-NT) is an anabolic andro-
genic steroid (AAS) produced first for androgen replacement
therapy as a testosterone analog. Due to its higher potency than
testosterone itself it has been misused for doping purposes and
forbidden in sports in 1976 (Hemmersbach and Grosse, 2010).
Since then, and despite the appearance of other doping products,
19-NT preparations have remained one of the most abused sub-
stances in sports (WADA Adverse Analytical Findings and Atypical
Findings, 2010, Montreal, Canada; www.wada-ama.org) as well as
in the society (Eklof et al., 2003).
19-NT is mainly metabolized into 19-norandrosterone (19-
NA) prior to glucuronidation and excretion via urine. Whereas
19-NT is known to be detectable in the serum for only 2–5 weeks
after injection (Bagchus et al., 2005), urinary 19-NA in its glu-
curonidated form is detectable up to 1 year after injection of 19-NT
and this excretion is prone to very large inter-individual variation
(Kintz et al., 2001; Bagchus et al., 2005; Garevik et al., 2011).
Uridine 5′-diphospho-glucuronosyl transferases (UGTs) are
known to be responsible for the final metabolism of many xenobi-
otics prior to their excretion in urine. Among the different UGTs
family, UGT2B7, UGT2B15, and UGT2B17 are known to have a
high capacity to conjugate androgens (Turgeon et al., 2001). A
marked stereoselectivity in the activity of UGT enzymes was evi-
denced using recombinant enzyme assays. UGT2B7 and UGT2B17
catalyze the conjugation of androgens at the 3α-OH and the 17β-
OH positions (Beaulieu et al., 1996; Jin et al., 1997; Coffman et al.,
1998; Gall et al., 1999), whereas UGT2B15 has been reported
to be a 17β-OH selective enzyme (Green et al., 1994; Kuuranne
et al., 2003). To date, one study using selected UGT recombinants
enzymes showed that 19-NA is mainly metabolized by UGT1A4
and UGT2B7 and, to a lesser extent, UGT1A1, UGT1A3, and
UGT2B4 (Kuuranne et al., 2003).
Several genetic polymorphisms in UGTs have been reported to
have an impact on their ability to metabolize androgens. A fre-
quent polymorphism in UGT2B7 gene leading to a histidine to
tyrosine substitution in codon 268 (H268Y) has shown variable
functional impact with different substrates (Ritter et al., 1990; Jin
et al., 1993; Coffman et al., 1998; Swanson et al., 2007). A relevant
polymorphism leading to an aspartic acid to tyrosine substitution
in codon 85 (D85Y) in the UGT2B15 gene was described (Chen
et al., 1993; Levesque et al., 1997). The genotype YY was reported
to be twice more active than DD on DHT that lead to a better
protection against high androgen level and decrease the risk of
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prostate cancer (Levesque et al., 1997; MacLeod et al., 2000). A
deletion polymorphism of the UGT2B17 gene has been identified
(Murata et al., 2003; Wilson et al., 2004) and correlated to glu-
curoconjugation of testosterone (Jakobsson et al., 2006). A lack
of this gene leads to a crucial decrease in urinary testosterone
even after a testosterone injection (Schulze et al., 2008). However,
there are no studies reporting UGT2B genetic variation and 19-NA
glucuronidation activity.
The aim of this study was to identify the influence of UGT2B7,
UGT2B15, and UGT2B17 genetic polymorphisms on 19-NA
glucuronidation in order to better understand the large inter-
individual variation in nandrolone elimination. Moreover, we
investigated if supra-physiological doses of androgens affect the
gene expression of UGT2B enzyme genes in HepG2 cells.
MATERIALS AND METHODS
LIVER SAMPLES
Fifty human liver tissue samples were obtained from human
donors to our human liver bank (approved by the Ethics Review
Board in Stockholm at Karolinska Institutet). The livers were
homogenized in 50 mM potassium phosphate buffer (pH 7.4) and
stored at −80°C until use. The human liver microsomes (HLM)
were prepared according to standard procedure (von Bahr et al.,
1980) and stored in 50 mM potassium phosphate buffer (pH 7.4)
at -80°C until use. The protein concentration was determined
according to Lowry et al. (1951).
GENOTYPING
Genomic DNA from human liver homogenate was obtained
using QIAmp DNA Blood Mini Kit from Qiagen (Hilden, Ger-
many). UGT2B7 polymorphism (rs7439366) which alter the
amino acid sequence Histidine (H) to Tyrosine (Y) at posi-
tion 268 were investigated by 5′nuclease activity method, using
upper primer AGCTGACGTATGGCTTATTCGAA and lower
primer GGGTTTGGCAGGTTTGCA (Cybergen, Stockholm, Swe-
den) and probes FAM-TTCAGTTTCCATATCCAC and VIC-
TTCAGTTTCCTCATCCACT (Applied Biosystems). UGT2B15
polymorphism (rs1902023) altering the amino acid sequence
Tyrosine (Y) to Aspartic acid (D) at position 85 was investigated
by 5′nuclease activity method using Taqman SNP Genotyping
Assay C–27028164_10 from Applied Biosystems. The PCR reac-
tion was carried out in 15µL volume including 1–3µL of genomic
DNA, 2×Taqman universal master mix, and run on an ABI 7500
Fast from Applied Biosystems. The PCR method consisted of
an initial denaturation step at 95°C for 10 min followed by 40
cycles of denaturation for 15 s and annealing/elongation at 60°C
for 1 min. The UGT2B17 deletion polymorphism was performed
by real-time PCR analysis as described elsewhere (Schulze et al.,
2008).
GLUCURONIDATION ACTIVITY IN HUMAN LIVER MICROSOME AND
INHIBITION STUDY
Chemicals
Methanol, n-pentane, potassium dihydrogenophosphate
(KH2PO4), potassium hydrogenophosphate (K2HPO4), natrium
carbonate (Na2CO3), magnesium chloride (MgCl2), and
ethanethiol were provided by Merck (Darmstadt, Germany).
Tris HCl, uridine 5′-diphospho-glucuronic acid (UDPGA) and
natrium hydrogenocarbonate (NaHCO3) and ammonium iodide
(NH4I), methyltestosterone (MeT), gemfibrozil, valproic acid,
and testosterone enanthate (TE) were provided by Sigma-
Aldrich Chemie GmbH (Munich, Germany). β-glucuronidase
from Escherichia coli (E coli) was provided by Roche Diagnos-
tics GmbH (Mannheim, Germany). N-methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA), were provided by Macherey-Nagel
GmbH (Düren, Germany), Ultrapur water was obtained with a
Milli-Q Reference Ultrapure Water Purification system equipped
with a Q-Gard T1 purification pack and a BioPak Point-of-
Use ultrafilter from Millipore (Billerica, MA, USA). Nandrolone
decanoate (19-NTD), 19-norandrosterone (19-NA), and 19-
norandrosterone glucuronide (19-NAG) were purchased from
NMI (Pymble, Australia)-Hecogenin acetate was provided by
Tokyo Chemical Industry Co. (Tokyo, Japan).
SAMPLE PREPARATION
Human liver microsomes samples were thawed at 25°C and the
volume equivalent to a final protein concentration of 1.0 mg/mL
was spiked in a glass tube containing the 19-NA required for the
assay. The final reaction volume of 50µL was obtained by addi-
tion of Tris HCl 50 mM pH 7.4 containing UDGPA 20 mM and
MgCl2 50 mM. Inhibition assays were performed using specific
UGTs inhibitors, hecogenin acetate at 10µM for UGT1A4 inhi-
bition, gemfibrozil 10µM for UGT2B7, and valproic acid 1 mM
for UGT2B15. After incubation during the required time at 37°C
in a stirring bath, the reaction was stopped by addition of 2 mL
n-pentane. A liquid-liquid extraction (LLE) with two times 2 mL
n-pentane was performed to retrieve the free steroids. The organic
phase was collected in a new glass tube containing 100 ng MeT
as internal standard and evaporated to dryness under an air flow.
Steroids were finally derivatized at 60°C for 30 min with 50µL
MSTFA/NH4I/Ethanethiol (10:0.02:0.03, v/w/v) prior to injection
onto GC-MS. The aqueous phase was treated by addition of 0.5 mL
phosphate buffer 1 M pH 7.0 and 70µL β-glucuronidase from
E. coli before incubation 60 min at 50°C. Then, 200 mg of solid
carbonate buffer [Na2CO3/NaHCO3, 1:10 (w/w)] was added to
reach a pH of 8.5–9.0. A LLE was performed using two times
2 mL n-pentane. The organic layer containing the deconjugated
steroid was collected in a new glass tube containing 100 ng MeT
as internal standard and evaporated to dryness under an air flow.
Steroids were finally derivatized at 60°C for 30 min with 50µL of
MSTFA/NH4I/Ethanethiol prior to injection onto GC-MS.
GC-MS ANALYSIS
The androgens quantification was performed on a gas chromatog-
raphy system Agilent 6890 (Palo Alto, CA, USA) equipped with
a column Agilent HP-1 (17 m× 0.2 mm I.D., 0.11µm) and cou-
pled to a mass analyzer Agilent 5973. A constant helium flow of
0.8 mL/min was applied on to the GC. The extracted sample (2µL)
was injected in the split mode (1:10). The temperatures were set
at 250, 280, 150, and 230°C for the injector, transfer line, quadru-
pole, and ionization source, respectively. The GC oven temperature
program was set as follow: hold 120°C for 1 min before gradi-
ent increase at 10°C/min to 200°C, then 2°C/min to 210°C, and
finally at 40°C/min to 310°C and maintained 2 min before the next
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analysis. The ionization was performed at 70 eV. The compound
identification was performed in the SCAN mode (m/z 50–500)
with a scan time of 2.48 scan/s. The quantification was performed
in the SIM mode with an analysis time of 30 ms/ion. Identity of
19-NA was controlled by the stability of the peak area ratios for
m/z 405, 420, 315, 225, and 169. The ion with m/z 405 was cor-
rected by MeT peak area (m/z 446) as internal standard and used
for quantification.
UGT2B mRNA EXPRESSION IN HepG2 CELLS AFTER INCUBATION WITH
ANDROGENS
Human liver cancer HepG2 cells from ATCC (Manassas, VA,
USA) were cultured in MEM supplemented with 10% fetal bovine
serum from the same provider and maintained in an incubator
in humidified atmosphere at 37°C and 5% CO2. Prior to andro-
gen treatment, the HepG2 cells were split in 12-well plates and
pre-incubated for 2–3 days. Nandrolone decanoate and TE were
diluted in ethanol to 1µM and added to the cells for 2 h prior
to harvest using Trizol from Invitrogen (Carlsbad, CA, USA). The
non-treated controls were incubated with vehicle only. The exper-
iments were performed at eight independent times. Total RNA
extraction from HepG2 cells was performed using 0.5 mL Trizol
per well according to manufacturer’s instructions. RNA (0.5µg)
was reverse transcribed into cDNA with hexamer primer using
first-strand cDNA synthesis kit from Invitrogen according to the
manufacturer’s protocol and diluted 20 times in water.
The mRNA levels of UGT2B7, 2B15 and 2B17 in nandrolone
treated HepG2s were determined by real-time PCR. Beta-actin
(#4326315E) from Applied Biosystems was chosen as an endoge-
nous housekeeping control gene. Quantitative real-time PCR was
performed using the ABI 7500 Fast. Reaction mixtures contained
SYBR green reaction mix from Kapa Biosystems (Woburn, MA,
USA), UGTs primers from Cybergene for UGT2B7, UGT2B15,
and UGT2B17 as described (Chouinard et al., 2006), 4µL cDNA
template in a total volume of 15µL. Thermal cycling conditions
included activation at 95°C for 10 min followed by 40 cycles of
denaturation at 95°C for 15 s and annealing/elongation at 60°C for
1 min. Each reaction was performed in duplicate and no-template
controls were included in each experiment. The untreated sample
was employed as a calibrator and the delta CT-formula was used
as described elsewhere (Schmittgen and Livak, 2008). The gene
expression was quantified as the yield of the target gene relative to
that of β-actin gene.
DATA ANALYSIS
Statistical analysis was performed using GraphPad Prism Software
v 4.3 (San Diego, CA, USA). The genotype association analysis
was calculated using one-way ANOVA and the mRNA expression
levels in androgen and vehicle exposed cells were compared using
Student’s t -test. Data are presented as mean± SD.
RESULTS
HUMAN LIVER MICROSOMES ASSAYS – INHIBITION STUDIES
Less than 1.5% of free 19-NA was detectable in 19-NAG solutions,
and 19-NAG remained stable in the buffer without HLM when
warmed at 37°C for 100 min. No increase of 19-NA concentration
was observed. The inhibition assay showed a significant inhibition
of 19-NAG production by 35± 11% for UGT2B7 (p= 0.04) and
45± 12% for UGT2B15 (p= 0.03) specific inhibitors valproic acid
and gemfibrozil (Figure 1). No significant inhibition was observed
with the UGT1A4 inhibitor hecogenin.
GENETIC VARIATION AND 19-NA GLUCURONIDATION
UGT2B7 H268Y genotype was determined for 50 HLM prepared
from our liver bank [YY (n= 12), YH (n= 25), HH (n= 13)].
The same HLM were incubated with 19-NA to determine their
glucuronidation activity. No significant correlation between glu-
curonidation activity and UGT2B7 H268Y genotypes was revealed
(Figure 2A). The same analysis was performed for UGT2B15 D85Y
polymorphism. But due to problems during genotyping, only 42
of the HLM previously analyzed were genotyped [DD (n= 9),
YD (n= 22), YY (n= 11)]. UGT2B15 DD homozygotes showed a
significantly higher glucuronidation capacity than YD (p= 0.05)
and YY (p= 0.02) subjects (Figure 2B). No significant difference
in glucuronidation was observed between YD and YY genotypes.
There was no significant difference between gender and UGTs
glucuronidation activity.
Among all the HLM, nine microsomes of each UGT2B17
deletion polymorphism group (del/del, ins/del, ins/ins) were
selected. No significant difference was reported between genotypes
regarding glucuronidation activity (data not shown).
UGTs mRNA EXPRESSION IN HepG2 CELLS
UGT2B7 mRNA expression was significantly increased in human
liver HepG2 after incubation at 37°C for 2 h with 1µM nan-
drolone decanoate (p= 0.02) and TE (p= 0.04) compared to
FIGURE 1 | Percentage of 19-norandrosterone glucuronide produced
from 1µM 19-norandrosterone in presence of UGTs specific inhibitors
(hecogenin acetate 10µM for UGT1A4, gemfibrozil 10µM for UGT2B7,
and valproic acid 1 mM for UGT2B15) in human liver microsomes
(n=5) presented as mean±SD. Significant inhibition was found for the
UGT2B7 and UGT2B15 specific inhibitors.
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FIGURE 2 | Glucuronidation activity of 19-NA in human liver
microsomes in relation to (A) UGT2B7 and (B) UGT2B15
polymorphisms. There was no association between UGT2B7 (H268Y)
genotype and glucuronidation activity, whereas a significant association
between UGT2B15 (D85Y) polymorphism and glucuronidation activity
(ANOVA p=0.02) was observed.
incubation with the vehicle only (Figure 3A). UGT2B15 mRNA
expression was significantly increased only after incubation with
TE (p= 0.01) (Figure 3B).
DISCUSSION
The results of the inhibition study using UGT2B7 specific
inhibitor gemfibrozil confirmed that this UGT is involved in
the glucuronidation of the hydroxyl group in the 3α posi-
tion of 19-NA. This is in line with in vitro observations from
other studies (Jin et al., 1997; Coffman et al., 1998; Gall et al.,
1999). However, the specific inhibition of the UGT1A4 enzyme
by hecogenin acetate did not affect the HLM ability to glu-
curonidate 19-NA, which was previously suggested (Kuuranne
et al., 2003). Surprisingly, UGT2B15, known to be involved in the
glucuronidation of the 17β-OH position in androgens seems to
be involved in 19-NA glucuronidation since its specific inhibitor,
FIGURE 3 | (A) UGT2B7 and (B) UGT2B15 mRNA expression in HepG2
cells after 2 h incubation with 1µM 19-NT or testosterone enanthate (n=8)
presented as mean±SD. UGT2B7 mRNA levels were significantly
up-regulated by both androgens, whereas UGT2B15 was significantly
induced by testosterone enanthate.
valproic acid, inhibited about 45% of the HLM glucuronidation
activity.
The average glucuronidation activity in all tested HLM was of
84.5± 10.7 pmol/min/mg protein, that represents a glucuronida-
tion of about 85% of the initial 19-NA added to the samples.
This shows the high capacity of human liver microsome to con-
jugate 19-NA by glucuronidation. In addition to be excreted as
glucuronides, 19-NA is also sulfated to some degree (Strahm et al.,
2009) by cytosolic sulfotransferases.
A significantly higher glucuronidation activity was detected
in individuals homozygous for the UGT2B15 D allele as com-
pared to Y carriers. Information about the polymorphic variants
of UGT2B15 activity toward androgens is conflicting. An early
in vitro report indicated that the Y carriers show a higher activ-
ity than D carriers on dihydrotestosterone and androstane-3α,
17β-diol (Levesque et al., 1997), whereas another group reported
that the D carriers have a higher glucuronidation activity than the
Y carriers on the same androgens (Court et al., 2002).
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No correlation with the polymorphism UGT2B7 H268Y was
detected by us; which is in line with the results observed previously
that UGT2B7 polymorphism did not influence the androsterone
glucuronidation in HLM (Bhasker et al., 2000) and the serum level
of androsterone glucuronide (Swanson et al., 2007). Androsterone
is similar to 19-NA except with a methyl in the 19 position. As
expected, UGT2B17 deletion polymorphism did not affect the 19-
NA glucuronidation since this enzyme prefers glucuronidation of
steroids at 17β-OH position and consequently plays an impor-
tant role in testosterone glucuronidation (Jakobsson et al., 2006).
As reported elsewhere for other substrates (Gallagher et al., 2010;
Ekstrom et al., 2012) no sex differences in 19-NA glucuronidation
activity was observed.
UGT2B7 mRNA expression was increased in HepG2 cells after
incubation with 19-NT and TE whereas UGT2B15 mRNA expres-
sion was increased only after the incubation with TE. Our results
indicate that androgens induce enzymes involved in its own elim-
ination, which may further contribute to the inter-individual
variability in disposition of 19-NA after the administration of
nandrolone in healthy volunteers (Strahm et al., 2009) and in AAS
abusers (Garevik et al., 2011). UGT2B17 on the other hand was not
affected by androgen exposure of HepG2 cells. These results are
opposite to what have been found in prostate cancer cells, where
UGT2B15 and UGT2B17 has been shown to be down-regulated
by androgens (Guillemette et al., 1997).
In conclusion, we show here that UGT2B7 and UGT2B15
are the main UGTs responsible for the glucuronidation of
the main metabolite of nandrolone. However, only UGT2B15
D85Y polymorphism influences the glucuronidation of 19-
norandrosterone with an activity significantly higher for the DD
carriers. This could partly explain the inter-individual variation
in 19-norandrosterone excretion, but a clinical study of nan-
drolone kinetics in healthy volunteers or studies in authentic
nandrolone abusers would be required to confirm this hypothesis
in vivo.
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